Navigation Links
Arete Therapeutics Bolsters Management Team
Date:10/29/2008

Appoints Euan MacIntyre, Ph.D. as Senior Vice President of Drug Discovery

HAYWARD, Calif., Oct. 29 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today named D. Euan MacIntyre, Ph.D., to the newly-created position of Senior Vice President, Drug Discovery. Dr. MacIntyre brings over 20 years of pharmaceutical drug discovery and development leadership to Arete Therapeutics.

"We are extremely pleased to welcome Euan as a member of our executive management team, as his broad drug discovery expertise and disease-specific knowledge will bolster our ability to develop effective s-EH inhibitors," said James H. Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "Given his scientific accomplishments and exceptional track record in advancing discovery programs through clinical development, I am confident Euan will provide invaluable insights and leadership as we finalize our plans to initiate a phase II study of AR9281 to treat metabolic syndrome and build out our expertise in this unique area of biology."

Dr. MacIntyre comes to Arete after more than 22 years with Merck Research Laboratories, where he held positions of escalating importance, most recently as Vice President of Pharmacology. Under his leadership, Dr. MacIntyre's team identified and validated several compounds now commercially available or in clinical trials for a variety of diseases and conditions including emesis, diabetes, obesity, hypertension, hyperlipidemia, pain, urinary incontinence and immuno-inflammatory disorders. In addition to his experience in discovery and development, Dr. MacIntyre evaluated numerous in-licensing candidates and served as a member of several joint research committees for Merck's joint ventures and collaborations. Dr. MacIntyre received his Ph.D. in pharmacology and experimental pathology from the University of Cambridge. He was a post-doctoral fellow at the University of Cambridge and at Harvard Medical School before joining the faculty at his alma mater, the University of Glasgow. He holds several patents, is the author of approximately 150 peer-reviewed publications, and has presented at numerous national and international symposia.

About Arete Therapeutics Inc.

Arete Therapeutics is a well-funded, privately-held pharmaceutical company dedicated to the discovery and development of novel drugs to treat metabolic, inflammatory and cardiovascular disease. It is the world's leading company focused on s-EH (soluble epoxide hydrolase), an important enzyme for the metabolism of arachidonic acid, that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The company was founded by Dr. Bruce Hammock at the University of California, Davis, who discovered s-EH. To date, Arete has raised a total of $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures. For more information on Arete Therapeutics, please visit http://www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
2. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
7. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
8. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
9. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
Breaking Biology Technology:
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):